Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation

Lu Jing; Xu Junming

doi:10.3969/j.issn.1674-7445.2021.04.015

Volume 12 Issue 4

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(4): 472-476

Lu Jing, Xu Junming. Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 472-476. doi: 10.3969/j.issn.1674-7445.2021.04.015

Citation:

Lu Jing, Xu Junming. Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 472-476. doi: 10.3969/j.issn.1674-7445.2021.04.015

Citation:

Lu Jing, Xu Junming. Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 472-476. doi: 10.3969/j.issn.1674-7445.2021.04.015

PDF( 857 KB)

Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation

doi: 10.3969/j.issn.1674-7445.2021.04.015

Lu Jing,
Xu Junming^,

Department of General Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China

More Information

Corresponding author: Xu Junming, Email: xjmsh@hotmail.com
Received Date: 2021-04-01
Available Online: 2021-07-13
Publish Date: 2021-07-15

Abstract

Abstract

Primary liver cancer (liver cancer) is one of the main indications of liver transplantation. However, postoperative recurrence of liver cancer severely affects the long-term clinical efficacy of liver transplantation. Programmed cell death protein 1 (PD-1) is an immunosuppressive molecule. Activation of PD-1/programmed cell death protein-ligand 1 (PD-L1) signaling pathway plays a pivotal role in the immune tolerance of grafts. In recent years, immune checkpoint inhibitor(ICI), such as PD-1/PD-L1 inhibitor, has become one of the effective approaches to treat advanced liver cancer, whereas ICI can be applied in liver transplant recipients is highly controversial, and the efficacy and safety remain to be studied. In this article, the expression of PD-1/PD-L1 in liver allograft tissues, the mechanism of PD-1/PD-L1 inducing transplantation immune tolerance and clinical application of PD-1/PD-L1 inhibitor in liver transplantation for liver cancer were reviewed.
- Programmed cell death protein 1,
- Liver transplantation,
- Immune tolerance,
- Immune checkpoint inhibitor,
- Primary liver cancer,
- Nivolumab,
- Pembrolizumab,
- Atezolizumab,
- Durvalumab

FullText(HTML)

References(28)

References

[1]	陆才德, 房炯泽. 肝癌肝移植研究进展[J]. 浙江医学, 2020, 42(14): 1459-1463. DOI: 10.12056/j.issn.1006-2785.2020.42.14.2019-1181. LU CD, FANG JZ. Advances in liver transplantation for liver cancer[J]. Zhejiang Med J, 2020, 42(14): 1459-1463. DOI: 10.12056/j.issn.1006-2785.2020.42.14.2019-1181.
[2]	HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
[3]	DAI S, JIA R, ZHANG X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol, 2014, 290(1): 72-79. DOI: 10.1016/j.cellimm.2014.05.006.
[4]	潘思宇, 王志鑫, 周瀛, 等. PD-1/PD-L1信号通路在肝脏疾病中的功能及作用机制[J]. 临床肝胆病杂志, 2019, 35(3): 672-676. DOI: 10.3969/j.issn.1001-5256.2019.03.050. PAN SY, WANG ZX, ZHOU Y, et al. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J]. J Clin Hepatol, 2019, 35(3): 672-676. DOI: 10.3969/j.issn.1001-5256.2019.03.050.
[5]	UEKI S, CASTELLANETA A, YOSHIDA O, et al. Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation[J]. Hepatology, 2011, 54(1): 216-228. DOI: 10.1002/hep.24360.
[6]	MORITA M, FUJINO M, JIANG G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft[J]. Am J Transplant, 2010, 10(1): 40-46. DOI: 10.1111/j.1600-6143.2009.02859.x.
[7]	LIU Z, YU X, REN W, et al. CD152 and PD-1 down-regulation on CD8 T cells is associated with human acute liver allograft rejection[J]. Transplant Proc, 2014, 46(10): 3511-3514. DOI: 10.1016/j.transproceed.2014.06.079.
[8]	SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6): 1274-1282. DOI: 10.1016/j.jhep.2016.02.034.
[9]	AYALA-MAR S, DONOSO-QUEZADA J, GONZÁLEZ-VALDEZ J. Clinical implications of exosomal PD-L1 in cancer immunotherapy[J]. J Immunol Res, 2021: 8839978. DOI: 10.1155/2021/8839978.
[10]	LIU Y, LIU S, WU C, et al. PD-1-mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4⁺ and CD8⁺ T cells during BVDV infection in vitro[J]. Front Immunol, 2020, 11: 467. DOI: 10.3389/fimmu.2020.00467.
[11]	CHAUDHRI A, XIAO Y, KLEE AN, et al. PD-L1 binds to B7-1 only in cis on the same cell surface[J]. Cancer Immunol Res, 2018, 6(8): 921-929. DOI: 10.1158/2326-6066.CIR-17-0316.
[12]	DENG R, CASSADY K, LI X, et al. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease[J]. J Immunol, 2015, 194(2): 560-574. DOI: 10.4049/jimmunol.1402157.
[13]	STATHOPOULOU C, GANGAPLARA A, MALLETT G, et al. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells[J]. Immunity, 2018, 49(2): 247-263. DOI: 10.1016/j.immuni.2018.05.006.
[14]	CAI J, WANG D, ZHANG G, et al. The role of PD-1/PD-L1 axis in treg development and function: implications for cancer immunotherapy[J]. Onco Targets Ther, 2019, 12: 8437-8445. DOI: 10.2147/OTT.S221340.
[15]	LEUNG CS, YANG KY, LI X, et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells[J]. Genome Med, 2018, 10(1): 71. DOI: 10.1186/s13073-018-0581-y.
[16]	ONO Y, PEREZ-GUTIERREZ A, NAKAO T, et al. Graft-infiltrating PD-L1^hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance[J]. Hepatology, 2018, 67(4): 1499-1515. DOI: 10.1002/hep.29529.
[17]	DE TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6): 1631-1633. DOI: 10.1053/j.gastro.2017.01.063.
[18]	GASSMANN D, WEILER S, MERTENS JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research[J]. Transplant Direct, 2018, 4(8): e376. DOI: 10.1097/TXD.0000000000000814.
[19]	QIU J, TANG W, DU C. Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: a case report and literature review[J]. Curr Cancer Drug Targets, 2020, 20(9): 720-727. DOI: 10.2174/1568009620666200520084415.
[20]	VARKARIS A, LEWIS DW, NUGENT FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma[J]. Am J Gastroenterol, 2017, 112(12): 1895-1896. DOI: 10.1038/ajg.2017.387.
[21]	NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
[22]	TABRIZIAN P, FLORMAN SS, SCHWARTZ ME. PD-1 inhibitor as bridge therapy to liver transplantation?[J]. Am J Transplant, 2020, 21(5): 1979-1980. DOI: 10.1111/ajt.16448.
[23]	崔春晓, 杨柳晓, 王颖, 等. 肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响[J]. 中国临床医学, 2020, 27(3): 444-447. DOI: 10.12025/j.issn.1008-6358.2020.20201005. CUI CX, YANG LX, WANG Y, et al. The effect of PD-1 inhibitor treatment before liver transplantation on posttransplant rejection in liver cancer patients[J]. Chin J Clin Med, 2020, 27(3): 444-447. DOI: 10.12025/j.issn.1008-6358.2020.20201005.
[24]	MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631.
[25]	DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?[J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505.
[26]	CHAE YK, GALVEZ C, ANKER JF, et al. Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients[J]. Cancer Treat Rev, 2018, 63: 116-121. DOI: 10.1016/j.ctrv.2017.12.004.
[27]	FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2020, 82(6): 1490-1500. DOI: 10.1016/j.jaad.2019.07.005.
[28]	HU B, YANG XB, SANG XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review[J]. Med Oncol, 2019, 36(11): 94. DOI: 10.1007/s12032-019-1316-7.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (865) PDF downloads(396)

Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation

doi: 10.3969/j.issn.1674-7445.2021.04.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of PD-1/PD-L1 signaling pathway in immune response of liver transplantation

doi: 10.3969/j.issn.1674-7445.2021.04.015

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content